SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, has announced the appointment of Sarah M. Romano as chief financial officer, effective Aug. 3, 2026. Romano, who will be based in the United States, brings more than two decades of finance leadership experience in the medical technology and life sciences sectors. Her appointment comes as the company advances its global expansion strategy, including the pursuit of U.S. FDA approval for its SSi Mantra surgical robotic system.
Romano most recently served as CFO of Vicarious Surgical, where she led financial and operational initiatives to reduce cash burn, strengthen the balance sheet, and support strategic objectives. Prior to that, she held CFO roles at Entero Therapeutics and Kiora Pharmaceuticals, raising more than $100 million through public and private financings while overseeing strategic transactions, SEC reporting, and investor relations. Her extensive background in the med-tech space positions her to help SS Innovations navigate the financial complexities of bringing its surgical robotic system to the U.S. market.
SS Innovations develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The company’s product range includes its proprietary SSi Mantra surgical robotic system and its comprehensive suite of SSi Mudra surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.
The appointment of a seasoned CFO like Romano is a critical step for SS Innovations as it prepares to seek FDA approval for the SSi Mantra system. Obtaining regulatory clearance in the U.S. would open a significant market opportunity, potentially transforming the company's revenue trajectory and competitive standing. Romano's experience in raising capital and managing financial operations at other medical technology firms could prove invaluable in funding the costly clinical trials and regulatory processes required for FDA approval.
For the medical device industry, SS Innovations' progress is noteworthy because it aims to offer a more affordable robotic surgery option. Current systems like da Vinci are expensive, limiting access to robotic surgery primarily to well-funded hospitals in developed countries. If SS Innovations succeeds in bringing a cost-effective alternative to market, it could democratize robotic surgery, making it accessible to a larger portion of the global population. This aligns with the company's stated mission.
Investors and industry observers will be watching closely as Romano takes the helm of SSII's financial operations. The company's ability to execute its expansion strategy and achieve FDA approval will depend heavily on sound financial management. Romano's track record in reducing cash burn and strengthening balance sheets suggests she is well-suited to guide the company through this capital-intensive phase.
For more details, the full press release is available at https://ibn.fm/pAqlP. Forward-looking statements about the company's plans and prospects are subject to risks and uncertainties detailed in its SEC filings. The company undertakes no duty to update this information unless required by law.
